Susquehanna International Group’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $32.2K | Sell |
122,595
-32,364
| -21% | -$8.98K | ﹤0.01% | 12748 |
|
|
2025
Q4 | $43.6K | Buy |
154,959
+140,997
| +1,010% | +$50.3K | ﹤0.01% | 11797 |
|
|
2025
Q3 | $5.82K | Buy |
+13,962
| New | +$5.31K | ﹤0.01% | 12123 |
|
|
2024
Q3 | – | Sell |
-152,376
| Closed | -$66.1K | – | 12451 |
|
|
2024
Q2 | $66.1K | Buy |
+152,376
| New | +$75.8K | ﹤0.01% | 11280 |
|
|
2024
Q1 | – | Sell |
-76,872
| Closed | -$21.5K | – | 12690 |
|
|
2023
Q4 | $21.5K | Buy |
76,872
+22,321
| +41% | +$6.92K | ﹤0.01% | 11957 |
|
|
2023
Q3 | $19.6K | Sell |
54,551
-20,607
| -27% | -$7.37K | ﹤0.01% | 11605 |
|
|
2023
Q2 | $23.4K | Sell |
75,158
-13,564
| -15% | -$4.39K | ﹤0.01% | 11600 |
|
|
2023
Q1 | $30.1K | Buy |
88,722
+10,582
| +14% | +$3.97K | ﹤0.01% | 11906 |
|
|
2022
Q4 | $24.9K | Sell |
78,140
-43,527
| -36% | -$17.8K | ﹤0.01% | 11689 |
|
|
2022
Q3 | $52K | Sell |
121,667
-56,772
| -32% | -$30.2K | ﹤0.01% | 12172 |
|
|
2022
Q2 | $94K | Buy |
178,439
+58,462
| +49% | +$36.9K | ﹤0.01% | 11536 |
|
|
2022
Q1 | $114K | Sell |
119,977
-168,178
| -58% | -$163K | ﹤0.01% | 11807 |
|
|
2021
Q4 | $281K | Sell |
288,155
-6,967
| -2% | -$9.35K | ﹤0.01% | 10644 |
|
|
2021
Q3 | $437K | Sell |
295,122
-119,324
| -29% | -$193K | ﹤0.01% | 9734 |
|
|
2021
Q2 | $680K | Sell |
414,446
-75,910
| -15% | -$116K | ﹤0.01% | 8816 |
|
|
2021
Q1 | $878K | Buy |
490,356
+218,536
| +80% | +$397K | ﹤0.01% | 8074 |
|
|
2020
Q4 | $424K | Buy |
271,820
+127,965
| +89% | +$189K | ﹤0.01% | 8623 |
|
|
2020
Q3 | $150K | Buy |
+143,855
| New | +$146K | ﹤0.01% | 9682 |
|
|
2020
Q2 | – | Sell |
-10,134
| Closed | -$5K | – | 10474 |
|
|
2020
Q1 | $5K | Sell |
10,134
-660
| -6% | -$366 | ﹤0.01% | 10104 |
|
|
2019
Q4 | $7K | Sell |
10,794
-46,540
| -81% | -$38.1K | ﹤0.01% | 9566 |
|
|
2019
Q3 | $56K | Buy |
57,334
+4,075
| +8% | +$4.91K | ﹤0.01% | 9744 |
|
|
2019
Q2 | $87K | Buy |
53,259
+32,509
| +157% | +$45.9K | ﹤0.01% | 9666 |
|
|
2019
Q1 | $43K | Buy |
+20,750
| New | +$47.2K | ﹤0.01% | 8494 |
|
|
2018
Q2 | – | Sell |
-45,157
| Closed | -$25K | – | 9952 |
|
|
2018
Q1 | $25K | Buy |
45,157
+24,936
| +123% | +$20.4K | ﹤0.01% | 9097 |
|
|
2017
Q4 | $20K | Buy |
+20,221
| New | +$11.2K | ﹤0.01% | 9063 |
|
|
2016
Q2 | – | Sell |
-28,727
| Closed | -$15K | – | 8891 |
|
|
2016
Q1 | $15K | Buy |
+28,727
| New | +$8.7K | ﹤0.01% | 8847 |
|
Other funds holding IGC
VCM
VFT
LC
DP
Susquehanna International Group's IGC Position: Q1 2026 in Review
Susquehanna International Group reduced its IGC Pharma (IGC) stake by 21% in Q1 2026, selling an estimated $8.98K and leaving 122,595 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #12748.
Susquehanna International Group first reported a position in IGC in Q1 2016 and has held it in 26 quarters since. The position peaked at $878K in Q1 2021. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.
- Susquehanna International Group held 122,595 shares of IGC Pharma worth $32.2K as of Q1 2026.
- Susquehanna International Group sold 32,364 IGC Pharma shares in Q1 2026, an estimated $8.98K.
- IGC Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12748 holding.
- Susquehanna International Group first reported a position in IGC Pharma in Q1 2016 and has held it in 26 quarters since.
- Susquehanna International Group's IGC Pharma position peaked at $878K in Q1 2021.
- 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.